Oxidative Stress: A Key Modulator in Neurodegenerative Diseases.
TL;DR: A need to understand the processes and role of oxidative stress in neurodegenerative diseases is understood, with a focus on the pivotal role played by OS in mitochondrial dysfunction.
read more
Abstract: Oxidative stress is proposed as a regulatory element in ageing and various neurological disorders. The excess of oxidants causes a reduction of antioxidants, which in turn produce an oxidation–reduction imbalance in organisms. Paucity of the antioxidant system generates oxidative-stress, characterized by elevated levels of reactive species (oxygen, hydroxyl free radical, and so on). Mitochondria play a key role in ATP supply to cells via oxidative phosphorylation, as well as synthesis of essential biological molecules. Various redox reactions catalyzed by enzymes take place in the oxidative phosphorylation process. An inefficient oxidative phosphorylation may generate reactive oxygen species (ROS), leading to mitochondrial dysfunction. Mitochondrial redox metabolism, phospholipid metabolism, and proteolytic pathways are found to be the major and potential source of free radicals. A lower concentration of ROS is essential for normal cellular signaling, whereas the higher concentration and long-time exposure of ROS cause damage to cellular macromolecules such as DNA, lipids and proteins, ultimately resulting in necrosis and apoptotic cell death. Normal and proper functioning of the central nervous system (CNS) is entirely dependent on the chemical integrity of brain. It is well established that the brain consumes a large amount of oxygen and is highly rich in lipid content, becoming prone to oxidative stress. A high consumption of oxygen leads to excessive production of ROS. Apart from this, the neuronal membranes are found to be rich in polyunsaturated fatty acids, which are highly susceptible to ROS. Various neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), among others, can be the result of biochemical alteration (due to oxidative stress) in bimolecular components. There is a need to understand the processes and role of oxidative stress in neurodegenerative diseases. This review is an effort towards improving our understanding of the pivotal role played by OS in neurodegenerative disorders.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Antiglycoxidative properties of amantadine – a systematic review and comprehensive in vitro study
Miłosz Nesterowicz,Małgorzata Żendzian-Piotrowska,Jerzy Robert Ładny,Anna Zalewska,Mateusz Maciejczyk +4 more
TL;DR: In this paper , a comprehensive study based on various glycation and oxidation factors, determining the impact of amantadine on protein glycoxidation was performed, and the results showed that the drug exhibited weak antioxidant properties and a lack of antiglycation activity.
10
Repurposing artemisinins as neuroprotective agents: a focus on the PI3k/Akt signalling pathway
TL;DR: This paper illustrates that artemisinins could be repurposed as a neuroprotective agent by modulating the PI3k/Akt with subsequent inhibition of oxidative stress, neuroinflammation, and apoptosis.
10
The biological role of prolyl oligopeptidase and the procognitive potential of its peptidic inhibitors from food proteins.
TL;DR: In this article , the authors describe the physiological and pathological aspects of POP activity and the state-of-the-art of its peptidic inhibitors originating from food proteins, with a particular focus on their potential as cognition-enhancing agents.
10
Neuroprotective Effects of Casein-Derived Peptide Met-Lys-Pro (MKP) in a Hypertensive Model.
Asuka Matsuzaki Tada,Hamizah Shahirah Hamezah,Daijiro Yanagisawa,Shigehiro Morikawa,Ikuo Tooyama +4 more
TL;DR: The present study indicates that MKP shows neuroprotective effects in SHRSP rats by regulating cerebral circulation insufficiency and corticoid levels and may be a potential therapeutic strategy for hypertensive brain diseases such as cerebrovascular disease.
Phenolic Compounds of Therapeutic Interest in Neuroprotection
José Manuel Nájera-Maldonado,Ricardo Salazar,Patricia Alvarez-Fitz,Macdiel Acevedo-Quiroz,Eugenia Flores-Alfaro,Daniel Hernández-Sotelo,Mónica Espinoza-Rojo,Mónica Ramírez +7 more
TL;DR: The physiopathology of neurodegenerative diseases is outlined, followed by an overall classification of the phenolic compounds, and some clinical trials in which neuroprotective mechanisms were demonstrated in models of different neurodegenerative diseases are reviewed.
10
References
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
TL;DR: The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available.
Free Radicals in the Physiological Control of Cell Function
TL;DR: There is growing evidence that aging involves, in addition, progressive changes in free radical-mediated regulatory processes that result in altered gene expression.
•Journal Article
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,C. R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +17 more
9K
Mutation in the α-synuclein gene identified in families with Parkinson's disease
Mihael H. Polymeropoulos,Christian Lavedan,Elisabeth Leroy,Susan E. Ide,Anindya Dehejia,Amalia Dutra,Brian L. Pike,Holly Root,Jeffrey Rubenstein,Rebecca Boyer,Edward S. Stenroos,Settara C. Chandrasekharappa,Aglaia Athanassiadou,Theodore Papapetropoulos,William G. Johnson,Alice Lazzarini,Roger C. Duvoisin,Giuseppe Di Iorio,Lawrence I. Golbe,Robert L. Nussbaum +19 more
TL;DR: A mutation was identified in the α-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype.
Alpha-synuclein in Lewy bodies.
Maria Grazia Spillantini,Marie L. Schmidt,Virginia M.-Y. Lee,John Q. Trojanowski,Ross Jakes,Michel Goedert +5 more
TL;DR: Strong staining of Lewy bodies from idiopathic Parkinson's disease with antibodies for α-synuclein, a presynaptic protein of unknown function which is mutated in some familial cases of the disease, indicates that the LewY bodies from these two diseases may have identical compositions.